Related Experiment Video

Updated: Oct 19, 2025

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

14.9K

Establishment and application of population pharmacokinetics model of vancomycin in infants with meningitis

Jianwen Xu1, Yanting Zhu2, Peiguang Niu2

  • 1Department of Pharmacy, Fujian Maternity and Child Health Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, 350001, China; Department of Pharmacy, Affiliated First Hospital of Fujian Medical University, Fuzhou, Fujian, 350001, China.

Pediatrics and Neonatology
|September 21, 2021
PubMed

Insights

A population pharmacokinetics (PPK) model for vancomycin (VCM) was developed to individualize dosing in Chinese infants with meningitis. This model accurately predicts VCM trough concentrations, improving treatment strategies.

Area of Science:

  • Pharmacology
  • Pediatrics
  • Infectious Diseases

Background:

  • Meningitis in infants requires effective antibiotic treatment.
  • Vancomycin (VCM) is a critical antibiotic for bacterial meningitis.
  • Optimizing VCM dosing is essential for therapeutic success and minimizing toxicity.

Purpose of the Study:

  • To develop a population pharmacokinetics (PPK) model for vancomycin (VCM).
  • To enable individualized VCM dose adjustments in Chinese infants diagnosed with meningitis.
  • To enhance therapeutic outcomes and safety profiles for VCM treatment in this pediatric population.

Main Methods:

  • Collected pharmacokinetic data from 82 pediatric patients with meningitis.
  • Utilized nonlinear mixed-effects modeling software to construct the PPK model.
  • Validated the model's predictive performance in a separate cohort of 20 infants.

Main Results:

  • Vancomycin clearance (CL) was positively correlated with body weight (WT) and negatively with blood urea nitrogen (BUN).
  • Co-administered medications did not significantly impact VCM pharmacokinetic parameters.
  • The developed PPK model demonstrated high accuracy in predicting VCM trough concentrations, with prediction errors below 32%.

Conclusions:

  • A novel individualized vancomycin (VCM) dosing strategy was proposed.
  • The PPK model provides a validated tool for optimizing VCM regimens in pediatric meningitis patients.
  • This approach facilitates personalized VCM therapy, potentially improving treatment efficacy and safety.
Abstract

Keywords:
NONMEMinfantsmeningitispopulation pharmacokineticsvancomycin

More Related Videos

Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study09:18

Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study

Published on: March 31, 2022

2.8K
Establishment and Optimization of a High Throughput Setup to Study Staphylococcus epidermidis and Mycobacterium marinum Infection as a Model for Drug Discovery10:19

Establishment and Optimization of a High Throughput Setup to Study Staphylococcus epidermidis and Mycobacterium marinum Infection as a Model for Drug Discovery

Published on: June 26, 2014

13.4K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
37
Estimation of k and VD of Aminoglycosides01:20

Estimation of k and VD of Aminoglycosides

Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
30
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
448
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
22
Two-Compartment Open Model: IV Infusion01:15

Two-Compartment Open Model: IV Infusion

A two-compartment model is a vital tool in pharmacokinetics, providing an essential understanding of drug behavior, especially for those administered via zero-order intravenous infusion. This model outlines two compartments: the central compartment, where elimination occurs, and the peripheral compartment.
The model illustrates the decrease in plasma drug concentration from the central compartment with a specific equation. It shows that under steady-state conditions, the drug's input rate...
372
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
35